

Benjamin M Greenberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3397191/publications.pdf>

Version: 2024-02-01

171
papers

9,721
citations

66343

42
h-index

39675

94
g-index

178
all docs

178
docs citations

178
times ranked

8740
citing authors

#	ARTICLE	IF	CITATIONS
1	Pediatric paraneoplastic neuromyelitis optica spectrum disorder associated with ovarian teratoma. <i>Multiple Sclerosis Journal</i> , 2022, 28, 160-163.	3.0	4
2	COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	26
3	CSF-Derived CD4+ T-Cell Diversity Is Reduced in Patients With Alzheimer Clinical Syndrome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, e1106.	6.0	11
4	Gene-environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1330-1339.	3.0	8
5	<scp>Aptamer-Based</scp> Screen of Neuropsychiatric Lupus Cerebrospinal Fluid Reveals Potential Biomarkers That Overlap With the Choroid Plexus Transcriptome. <i>Arthritis and Rheumatology</i> , 2022, 74, 1223-1234.	5.6	6
6	Cryptococcal Meningitis Reported With Fingolimod Treatment. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	11
7	Association Between Time Spent Outdoors and Risk of Multiple Sclerosis. <i>Neurology</i> , 2022, 98, .	1.1	12
8	Determining Prevalence of Depression and Covariates of Depression in a Cohort of Multiple Sclerosis Patients. <i>Journal of Central Nervous System Disease</i> , 2022, 14, 117957352210981.	1.9	2
9	A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHlgM22 in subjects with multiple sclerosis immediately following a relapse. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732210914.	1.0	2
10	Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAKuraSky and SAKuraStar. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 66, 104025.	2.0	15
11	Letter to the Editor Regarding "Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder". <i>Neurology and Therapy</i> , 2022, 11, 1439-1443.	3.2	4
12	Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 922-932.	3.0	5
13	Clinical Features, Treatment Strategies, and Outcomes in Hospitalized Children With Immune-Mediated Encephalopathies. <i>Pediatric Neurology</i> , 2021, 116, 20-26.	2.1	8
14	Selective Depletion of Antigen-Specific Antibodies for the Treatment of Demyelinating Disease. <i>Molecular Therapy</i> , 2021, 29, 1312-1323.	8.2	20
15	Neurological infections in 2020: COVID-19 takes centre stage. <i>Lancet Neurology</i> , The, 2021, 20, 17-18.	10.2	3
16	Acute flaccid myelitis: cause, diagnosis, and management. <i>Lancet</i> , The, 2021, 397, 334-346.	13.7	88
17	Clinical Approach to Autoimmune Myelitis and Myelopathy. , 2021, , 433-445.		0
18	Bladder management in children with transverse myelitis. <i>Journal of Pediatric Urology</i> , 2021, 17, 522.e1-522.e6.	1.1	2

#	ARTICLE	IF	CITATIONS
19	Physician Compensation in the United States â€œ Through the Lens of the MS Neurologist. Multiple Sclerosis and Related Disorders, 2021, 50, 102847.	2.0	0
20	Acute flaccid myelitis: long-term outcomes recorded in the CAPTURE study compared with paediatric transverse myelitis. BMJ Neurology Open, 2021, 3, e000127.	1.6	6
21	Molecular Level Characterization of Circulating Aquaporin-4 Antibodies in Neuromyelitis Optica Spectrum Disorder. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	16
22	Reconstituting T cell receptor selection in-silico. Genes and Immunity, 2021, 22, 187-193.	4.1	2
23	Familial History of Autoimmune Disorders Among Patients With Pediatric Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	4
24	In-Depth Evaluation of a Case of Presumed Myocarditis After the Second Dose of COVID-19 mRNA Vaccine. Circulation, 2021, 144, 487-498.	1.6	102
25	A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica. Annals of Clinical and Translational Neurology, 2021, 8, 2025-2037.	3.7	20
26	Increased Prevalence of Familial Autoimmune Disease in Children With Opsoclonus-Myoclonus Syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1079.	6.0	2
27	Asymptomatic retinal vasculopathy in neuropsychiatric systemic lupus erythematosus. Journal of the Neurological Sciences, 2021, 430, 118053.	0.6	2
28	Utilization and Treatment Patterns of Disease-Modifying Therapy in Pediatric Patients with Multiple Sclerosis in the United States. International Journal of MS Care, 2021, 23, 101-105.	1.0	5
29	Interocular Difference in Retinal Nerve Fiber Layer Thickness Predicts Optic Neuritis in Pediatric-Onset Multiple Sclerosis. Journal of Neuro-Ophthalmology, 2021, 41, 469-475.	0.8	5
30	The princess and the <i>p</i>-value: A case report of suspected autoimmune encephalitis and functional neurological disorder in a pediatric patient. Applied Neuropsychology: Child, 2020, 9, 13-20.	1.4	2
31	Vitamin D genes influence MS relapses in children. Multiple Sclerosis Journal, 2020, 26, 894-901.	3.0	17
32	Two cases of aquaporin-4 positive neuromyelitis optica associated with T-cell lymphoma. Journal of Neuroimmunology, 2020, 338, 577092.	2.3	8
33	Revisiting Transverse Myelitis: Moving Toward a New Nomenclature. Frontiers in Neurology, 2020, 11, 519468.	2.4	5
34	Home-Based Pediatric Teleneuropsychology: A validation study. Archives of Clinical Neuropsychology, 2020, 35, 1266-1275.	0.5	43
35	Heterozygous Cystic Fibrosis Transmembrane Regulator Gene Missense Variants Are Associated With Worse Cardiac Function in Patients With Duchenne Muscular Dystrophy. Journal of the American Heart Association, 2020, 9, e016799.	3.7	5
36	Limitations of cell-lineage-specific non-dynamic gene recombination in CD11c.Cre+ITGA4fl/fl mice. Journal of Neuroimmunology, 2020, 344, 577245.	2.3	5

#	ARTICLE	IF	CITATIONS
37	Multiple sclerosis relapse rates and healthcare costs of two versions of glatiramer acetate. <i>Current Medical Research and Opinion</i> , 2020, 36, 1167-1175.	1.9	2
38	Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGM study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 483-492.	1.9	26
39	Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. <i>Lancet Neurology</i> , The, 2020, 19, 402-412.	10.2	278
40	Retroperitoneal approach for the treatment of diaphragmatic crus syndrome: technical note. <i>Journal of Neurosurgery: Spine</i> , 2020, 33, 114-119.	1.7	1
41	Author response: Progressive multifocal leukoencephalopathy after fingolimod treatment. <i>Neurology</i> , 2019, 92, 151.2-151.	1.1	0
42	New onset transverse myelitis diagnostic accuracy and patient experiences. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 30, 42-44.	2.0	7
43	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , The, 2019, 18, 185-197.	10.2	110
44	Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. <i>PLoS Genetics</i> , 2019, 15, e1007808.	3.5	48
45	mi RNA contributions to pediatric-onset multiple sclerosis inferred from GWAS. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1053-1061.	3.7	10
46	Clinical Approach to Pediatric Transverse Myelitis, Neuromyelitis Optica Spectrum Disorder and Acute Flaccid Myelitis. <i>Children</i> , 2019, 6, 70.	1.5	12
47	Acute Disseminated Encephalomyelitis (ADEM) and Increased Intracranial Pressure Associated With Anti-Myelin Oligodendrocyte Glycoprotein Antibodies. <i>Pediatric Neurology</i> , 2019, 99, 64-68.	2.1	14
48	Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. <i>New England Journal of Medicine</i> , 2019, 381, 2114-2124.	27.0	383
49	Unique characteristics of optical coherence tomography (OCT) results and visual acuity testing in myelin oligodendrocyte glycoprotein (MOG) antibody positive pediatric patients. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 86-90.	2.0	42
50	Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis. <i>Journal of Child Neurology</i> , 2019, 34, 148-152.	1.4	5
51	Atypical Anti-MOG syndrome with aseptic meningoencephalitis and pseudotumor cerebri-like presentations. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 30-33.	2.0	48
52	Assessment of Renal Deterioration and Associated Risk Factors in Patients With Multiple Sclerosis. <i>Urology</i> , 2019, 123, 76-80.	1.0	8
53	Progressive multifocal leukoencephalopathy after fingolimod treatment. <i>Neurology</i> , 2018, 90, e1815-e1821.	1.1	123
54	Early infectious exposures are not associated with increased risk of pediatric-onset multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 103-107.	2.0	2

#	ARTICLE	IF	CITATIONS
55	What is causing this patient's headache and seizures?. JAAPA: Official Journal of the American Academy of Physician Assistants, 2018, 31, 56-57.	0.3	0
56	Dietary factors and pediatric multiple sclerosis: A case-control study. Multiple Sclerosis Journal, 2018, 24, 1067-1076.	3.0	27
57	Neuropsychological outcomes of pediatric demyelinating diseases: a review. Child Neuropsychology, 2018, 24, 575-597.	1.3	8
58	A Callosal Catastrophe: Toxic Leukoencephalopathy Associated with Thermogenic Weight Loss Supplement Use. Neurocritical Care, 2018, 29, 504-507.	2.4	2
59	Myelin oligodendrocyte glycoprotein-specific antibodies from multiple sclerosis patients exacerbate disease in a humanized mouse model. Journal of Autoimmunity, 2018, 86, 104-115.	6.5	26
60	Genetic risk factors for pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1825-1834.	3.0	37
61	Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis. Journal of Pharmacy Practice, 2018, 31, 481-488.	1.0	28
62	Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2018, 24, 1737-1742.	3.0	41
63	Pediatric Multiple Sclerosis. Neurologic Clinics, 2018, 36, 135-149.	1.8	14
64	Area postrema syndrome. Neurology, 2018, 91, e1642-e1651.	1.1	129
65	Heterogeneity in association of remote herpesvirus infections and pediatric <scp>MS</scp>. Annals of Clinical and Translational Neurology, 2018, 5, 1222-1228.	3.7	25
66	Urban air quality and associations with pediatric multiple sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1146-1153.	3.7	29
67	Several household chemical exposures are associated with pediatric-onset multiple sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1513-1521.	3.7	8
68	Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. New England Journal of Medicine, 2018, 379, 1017-1027.	27.0	237
69	A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica. Nature Communications, 2018, 9, 1929.	12.8	73
70	<i>BRAF</i> mutation leading to central nervous system rosai-Erdorfman disease. Annals of Neurology, 2018, 84, 147-152.	5.3	37
71	Anti-Myelin Oligodendrocyte Glycoprotein Antibody Associated With Gray Matter Predominant Transverse Myelitis Mimicking Acute Flaccid Myelitis: A Presentation of Two Cases. Pediatric Neurology, 2018, 86, 42-45.	2.1	22
72	Safety and efficacy of plasma exchange in pediatric transverse myelitis. Neurology: Clinical Practice, 2018, 8, 327-330.	1.6	17

#	ARTICLE	IF	CITATIONS
73	Neuroimmune disorders of the central nervous system in children in the molecular era. <i>Nature Reviews Neurology</i> , 2018, 14, 433-445.	10.1	41
74	Urodynamics findings in transverse myelitis patients with lower urinary tract symptoms: Results from a tertiary referral urodynamic center. <i>Neurourology and Urodynamics</i> , 2017, 36, 360-363.	1.5	19
75	Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric population. <i>Journal of the Neurological Sciences</i> , 2017, 375, 371-375.	0.6	5
76	Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. <i>Neurology</i> , 2017, 88, 1623-1629.	1.1	138
77	High-dose methotrexate with leucovorin rescue: For monumentally severe CNS inflammatory syndromes. <i>Journal of the Neurological Sciences</i> , 2017, 372, 187-195.	0.6	16
78	Examining the contributions of environmental quality to pediatric multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 164-169.	2.0	21
79	Analysis of 30 Spinal Angiograms Falsely Reported as Normal in 18 Patients with Subsequently Documented Spinal Vascular Malformations. <i>American Journal of Neuroradiology</i> , 2017, 38, 1814-1819.	2.4	26
80	Persistence of parenchymal and perivascular T-cells in treatment-refractory anti-N-methyl-D-aspartate receptor encephalitis. <i>NeuroReport</i> , 2017, 28, 890-895.	1.2	5
81	Peripheral VH4+Âplasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients. <i>Acta Neuropathologica</i> , 2017, 133, 43-60.	7.7	30
82	A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHlgM22 in people with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2017, 3, 205521731774309.	1.0	25
83	Statistical classifiers for diagnosing disease from immune repertoires: a case study using multiple sclerosis. <i>BMC Bioinformatics</i> , 2017, 18, 401.	2.6	57
84	Acute Disseminated Encephalomyelitis. , 2017, , .		0
85	Dietary salt intake and time to relapse in paediatric multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1350-1353.	1.9	58
86	Distinct effects of obesity and puberty on risk and age at onset of pediatric MS. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 897-907.	3.7	67
87	A case-control study of dietary salt intake in pediatric-onset multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 6, 87-92.	2.0	58
88	Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 211-215.	3.5	18
89	Induction of regulatory T-cells from memory T-cells is perturbed during acute exacerbation of multiple sclerosis. <i>Clinical Immunology</i> , 2016, 166-167, 12-18.	3.2	6
90	Diagnostic and therapeutic strategies for management of autoimmune encephalopathies. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 937-949.	2.8	29

#	ARTICLE	IF	CITATIONS
91	Pediatric transverse myelitis. <i>Neurology</i> , 2016, 87, S46-52.	1.1	92
92	Neurotherapeutic Strategies for Multiple Sclerosis. <i>Neurologic Clinics</i> , 2016, 34, 483-523.	1.8	7
93	CD40-Mediated NF- κ B Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics. <i>Journal of Immunology</i> , 2016, 197, 4257-4265.	0.8	45
94	Vitamin D During Pregnancy and Multiple Sclerosis. <i>JAMA Neurology</i> , 2016, 73, 498.	9.0	9
95	A Single Amino Acid Substitution Prevents Recognition of a Dominant Human Aquaporin-4 Determinant in the Context of HLA-DRB1*03:01 by a Murine TCR. <i>PLoS ONE</i> , 2016, 11, e0152720.	2.5	7
96	Does Autoimmunity have a Role in Myoclonic Astatic Epilepsy? A Case Report of Voltage Gated Potassium Channel Mediated Seizures. <i>Annals of Clinical Case Reports</i> , 2016, 1, .	0.6	0
97	Neuromyelitis Optica Spectrum Disorder Associated With Autoimmune Hemolytic Anemia and Lymphoma. <i>Neurologist</i> , 2015, 20, 33-34.	0.7	12
98	Equivalent Gene Expression Profiles between Glatopa $\text{\textcircled{R}}$ and Copaxone $\text{\textcircled{R}}$. <i>PLoS ONE</i> , 2015, 10, e0140299.	2.5	10
99	Placebo studies should not be undertaken in NMO â€“ No. <i>Multiple Sclerosis Journal</i> , 2015, 21, 691-693.	3.0	3
100	Immune-Mediated Myelopathies. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2015, 21, 121-131.	0.8	5
101	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015, 72, 815.	9.0	59
102	Peripheral Nerve Involvement in Adult and Pediatric Patients With Central Nervous System Inflammatory Diseaseâ€”Reply. <i>JAMA Neurology</i> , 2015, 72, 123.	9.0	0
103	Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. <i>Multiple Sclerosis Journal</i> , 2015, 21, 678-688.	3.0	209
104	Intravenous methylprednisolone versus therapeutic plasma exchange for treatment of anti- α -methylcrotonylcholinesterase receptor antibody encephalitis: A retrospective review. <i>Journal of Clinical Apheresis</i> , 2015, 30, 212-216.	1.3	68
105	MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencing. <i>Gene</i> , 2015, 572, 191-197.	2.2	17
106	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. <i>Neurology</i> , 2015, 85, 177-189.	1.1	3,275
107	Challenges and opportunities in designing clinical trials for neuromyelitis optica. <i>Neurology</i> , 2015, 84, 1805-1815.	1.1	39
108	A Distinct Class of Antibodies May Be an Indicator of Gray Matter Autoimmunity in Early and Established Relapsing Remitting Multiple Sclerosis Patients. <i>ASN Neuro</i> , 2015, 7, 175909141560961.	2.7	18

#	ARTICLE	IF	CITATIONS
109	The spectrum of autoimmune encephalopathies. <i>Journal of Neuroimmunology</i> , 2015, 287, 93-97.	2.3	46
110	Update on biomarkers in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e134.	6.0	104
111	The Antibody Genetics of Multiple Sclerosis: Comparing Next-Generation Sequencing to Sanger Sequencing. <i>Frontiers in Neurology</i> , 2014, 5, 166.	2.4	10
112	Elevated CNS Inflammation in Patients with Preclinical Alzheimer's Disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 30-33.	4.3	74
113	Herpes Simplex Encephalitis as a Potential Cause of Anti-N-Methyl-d-Aspartate Receptor Antibody Encephalitis. <i>JAMA Neurology</i> , 2014, 71, 344.	9.0	68
114	Transverse Myelitis Plus Syndrome and Acute Disseminated Encephalomyelitis Plus Syndrome. <i>JAMA Neurology</i> , 2014, 71, 624.	9.0	30
115	JC Virus in CD34 ⁺ and CD19 ⁺ Cells in Patients With Multiple Sclerosis Treated With Natalizumab. <i>JAMA Neurology</i> , 2014, 71, 596.	9.0	65
116	Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica. <i>JAMA Neurology</i> , 2014, 71, 324.	9.0	258
117	The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis. <i>JAMA Neurology</i> , 2014, 71, 1421.	9.0	73
118	Monocular and binocular low-contrast visual acuity and optical coherence tomography in pediatric multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 326-334.	2.0	41
119	Proteoform analysis of lipocalin-type prostaglandin synthase from human cerebrospinal fluid by isoelectric focusing and superficially porous liquid chromatography with Fourier transform mass spectrometry. <i>Proteomics</i> , 2014, 14, 1223-1231.	2.2	9
120	Disease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8 ⁺ T cells. <i>Clinical Immunology</i> , 2014, 152, 115-126.	3.2	46
121	Fatigue, emotional functioning, and executive dysfunction in pediatric multiple sclerosis. <i>Child Neuropsychology</i> , 2014, 20, 71-85.	1.3	38
122	Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. <i>Clinical and Experimental Immunology</i> , 2014, 175, 397-407.	2.6	68
123	Light Switch-Mental Status Changes and Irritable Insomnia are Two Particularly Salient Features of Anti-NMDA Receptor Antibody Encephalitis. <i>Pediatric Neurology</i> , 2014, 51, 151-153.	2.1	14
124	Three Phenotypes of Anti-N-Methyl-d-Aspartate Receptor Antibody Encephalitis in Children: Prevalence of Symptoms and Prognosis. <i>Pediatric Neurology</i> , 2014, 51, 542-549.	2.1	41
125	Expansion of CD27 ^{high} plasmablasts in transverse myelitis patients that utilize VH4 and JH6 genes and undergo extensive somatic hypermutation. <i>Genes and Immunity</i> , 2013, 14, 291-301.	4.1	10
126	Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis. <i>JAMA Neurology</i> , 2013, 70, 248.	9.0	13

#	ARTICLE	IF	CITATIONS
127	Top-Down Mass Spectrometry on Tissue Extracts and Biofluids with Isoelectric Focusing and Superficially Porous Silica Liquid Chromatography. <i>Analytical Chemistry</i> , 2013, 85, 10377-10384.	6.5	23
128	Blind and Confused. <i>JAMA Neurology</i> , 2013, 70, 932.	9.0	0
129	Cognitive functioning in pediatric transverse myelitis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 947-952.	3.0	8
130	A Surprisingly Low Prevalence of Demonstrable Stress Urinary Incontinence and Pelvic Organ Prolapse in Women with Multiple Sclerosis Followed at a Tertiary Neurogenic Bladder Clinic. <i>Journal of Urology</i> , 2013, 189, 976-979.	0.4	16
131	Transverse Myelitis. <i>Neurologic Clinics</i> , 2013, 31, 79-138.	1.8	172
132	Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis. <i>Clinical Immunology</i> , 2013, 147, 105-119.	3.2	21
133	Uhthoff's phenomena in MS—clinical features and pathophysiology. <i>Nature Reviews Neurology</i> , 2013, 9, 535-540.	10.1	70
134	Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy. <i>Neurology</i> , 2013, 80, 1862-1866.	1.1	35
135	Interferon Beta and Long-term Disability in Multiple Sclerosis—Reply. <i>JAMA Neurology</i> , 2013, 70, 651.	9.0	6
136	What Is the True Clinicopathologic Spectrum of Neuromyelitis Optica?—Reply. <i>JAMA Neurology</i> , 2013, 70, 272.	9.0	2
137	Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. <i>PLoS Pathogens</i> , 2012, 8, e1003014.	4.7	44
138	Human Aquaporin 4₂₈₁₋₃₀₀ Is the Immunodominant Linear Determinant in the Context of HLA-DRB1*03:01. <i>Archives of Neurology</i> , 2012, 69, 1125-31.	4.5	16
139	Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1022-1026.	3.0	105
140	Low Serum Vitamin D Levels and Recurrent Inflammatory Spinal Cord Disease. <i>Archives of Neurology</i> , 2012, 69, 352.	4.5	21
141	Antibody-independent B cell effector functions in relapsing remitting Multiple Sclerosis: Clues to increased inflammatory and reduced regulatory B cell capacity. <i>Autoimmunity</i> , 2012, 45, 400-414.	2.6	52
142	Multifocal visual evoked potentials are influenced by variable contrast stimulation in MS. <i>Neurology</i> , 2012, 79, 797-801.	1.1	23
143	Epidemiology of Neuromyelitis Optica in the United States. <i>Archives of Neurology</i> , 2012, 69, 1176-80.	4.5	239
144	Objective characterization of the relative afferent pupillary defect in MS. <i>Journal of the Neurological Sciences</i> , 2012, 323, 193-200.	0.6	13

#	ARTICLE	IF	CITATIONS
145	Current and emerging therapies in multiple sclerosis: a systematic review. <i>Therapeutic Advances in Neurological Disorders</i> , 2012, 5, 205-220.	3.5	112
146	Optic neuritis: A mechanistic view. <i>Pathophysiology</i> , 2011, 18, 81-92.	2.2	32
147	Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of multiple sclerosis. <i>Journal of Autoimmunity</i> , 2011, 36, 115-124.	6.5	68
148	No Cerebral or Cervical Venous Insufficiency in US Veterans With Multiple Sclerosis. <i>Archives of Neurology</i> , 2011, 68, 1521.	4.5	33
149	Treatment of Acute Transverse Myelitis and Its Early Complications. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2011, 17, 733-743.	0.8	10
150	Symptomatic therapy in multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2011, 4, 83-98.	3.5	33
151	Carotid Cavernous Fistula Imitating Brainstem Glioma. <i>Archives of Neurology</i> , 2011, 68, 256-7.	4.5	2
152	Predicting the Outcome of Shunt Surgery in Normal Pressure Hydrocephalus. <i>Neurosurgery</i> , 2010, 66, E1217.	1.1	0
153	CURRENT AND EMERGING MULTIPLE SCLEROSIS THERAPEUTICS. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2010, 16, 58-77.	0.8	6
154	Anticipated benefits and surprising effects of daclizumab in multiple sclerosis. <i>Lancet Neurology</i> , The, 2010, 9, 337-338.	10.2	6
155	Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4 ⁺ T cell proliferation and IFN γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. <i>European Journal of Immunology</i> , 2010, 40, 2942-2956.	2.9	114
156	Natalizumab and Progressive Multifocal Leukoencephalopathy. <i>Archives of Neurology</i> , 2010, 67, 923-30.	4.5	105
157	A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2010, 3, 15-28.	3.5	29
158	Optical coherence tomography as a potential readout in clinical trials. <i>Therapeutic Advances in Neurological Disorders</i> , 2010, 3, 153-160.	3.5	37
159	Pearls: Multiple Sclerosis. <i>Seminars in Neurology</i> , 2010, 30, 097-101.	1.4	4
160	Translational Research in Neurology and Neuroscience 2010. <i>Archives of Neurology</i> , 2010, 67, 1307-15.	4.5	11
161	Corrigendum. <i>Clinical Neuropsychologist</i> , 2010, 24, 1092-1092.	2.3	0
162	Direct and consensual murine pupillary reflex metrics: Establishing normative values. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2009, 151, 164-167.	2.8	19

#	ARTICLE	IF	CITATIONS
163	Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: A pilot study. <i>Journal of the Neurological Sciences</i> , 2009, 282, 96-105.	0.6	110
164	Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 735-740.	3.0	61
165	The Neurologic Manifestations of Systemic Lupus Erythematosus. <i>Neurologist</i> , 2009, 15, 115-121.	0.7	35
166	Future Research Directions in Multiple Sclerosis Therapies. <i>Seminars in Neurology</i> , 2008, 28, 121-127.	1.4	13
167	Central Nervous System Infections in the Intensive Care Unit. <i>Seminars in Neurology</i> , 2008, 28, 682-689.	1.4	12
168	Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis. <i>Archives of Neurology</i> , 2008, 65, 1044-51.	4.5	78
169	INFECTIOUS COMPLICATIONS OF TEMPORARY SPINAL CATHETER INSERTION FOR DIAGNOSIS OF ADULT HYDROCEPHALUS AND IDIOPATHIC INTRACRANIAL HYPERTENSION. <i>Neurosurgery</i> , 2008, 62, 431-436.	1.1	23
170	Bacteraemia in the elderly: predictors of outcome in an urban teaching hospital. <i>Journal of Infection</i> , 2005, 50, 288-295.	3.3	38
171	Clinical cases in neurology from Johns Hopkins. Case 2: acute ascending paralysis in a 4-year-old boy. <i>MedGenMed: Medscape General Medicine</i> , 2003, 5, 36.	0.2	1